Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Bio-pharma market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.6% during the forecast period.
This report presents the market size and development trends by detailing the Bio-pharma market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Bio-pharma market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Bio-pharma industry and will help you to build a panoramic view of the industrial development.
Bio-pharma Market, By Type:
Monoclonal Antibodies
Recombinant Proteins
Granulocyte-Colony Stimulating Factor (G-CSF)
Interferons
Recombinant Human Insulin
Erythropoietin
Vaccines
Growth Hormones
Purified Proteins
Others
Bio-pharma Market, By Application:
Metabolic Disorders
Oncology
Neurological Disorders
Cardiovascular Diseases
Inflammatory and Infectious Diseases
Others
Some of the leading players are as follows:
Novartis AG GlaxoSmithKline Plc
Abbott Laboratories
Merck & Co., Inc
AstraZeneca PLC
Pfizer
Bristol-Myers Squibb Company
Biogen Idec
F Hoffmann-La Roche AG
Bayer AG
AbbVie
Eli Lilly and Company
Merck & Co, Inc
F. Hoffmann-La Roche AG
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Bio-pharma Market: Technology Type Analysis
-
4.1 Bio-pharma Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Bio-pharma Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Monoclonal Antibodies
4.3.2 Recombinant Proteins
4.3.3 Granulocyte-Colony Stimulating Factor (G-CSF)
4.3.4 Interferons
4.3.5 Recombinant Human Insulin
4.3.6 Erythropoietin
4.3.7 Vaccines
4.3.8 Growth Hormones
4.3.9 Purified Proteins
4.3.10 Others
5 Bio-pharma Market: Product Analysis
-
5.1 Bio-pharma Product Market Share Analysis, 2018 & 2026
-
5.2 Bio-pharma Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Bio-pharma Market: Application Analysis
-
6.1 Bio-pharma Application Market Share Analysis, 2018 & 2026
-
6.2 Bio-pharma Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Metabolic Disorders
6.3.2 Oncology
6.3.3 Neurological Disorders
6.3.4 Cardiovascular Diseases
6.3.5 Inflammatory and Infectious Diseases
6.3.6 Others
7 Bio-pharma Market: Regional Analysis
-
7.1 Bio-pharma Regional Market Share Analysis, 2018 & 2026
-
7.2 Bio-pharma Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Novartis AG GlaxoSmithKline Plc
9.1.1 Novartis AG GlaxoSmithKline Plc Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Abbott Laboratories
9.2.1 Abbott Laboratories Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Merck & Co., Inc
9.3.1 Merck & Co., Inc Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 AstraZeneca PLC
9.4.1 AstraZeneca PLC Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Pfizer
9.5.1 Pfizer Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Bristol-Myers Squibb Company
9.6.1 Bristol-Myers Squibb Company Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Biogen Idec
9.7.1 Biogen Idec Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 F Hoffmann-La Roche AG
9.8.1 F Hoffmann-La Roche AG Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Bayer AG
9.9.1 Bayer AG Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 AbbVie
9.10.1 AbbVie Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Eli Lilly and Company
9.11.1 Eli Lilly and Company Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Merck & Co, Inc
9.12.1 Merck & Co, Inc Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 F. Hoffmann-La Roche AG
9.13.1 F. Hoffmann-La Roche AG Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
The List of Tables and Figures (Totals 78 Figures and 142 Tables)
Figure Monoclonal Antibodies Bio-pharma market, 2015 - 2026 (USD Million)
Figure Recombinant Proteins Bio-pharma market, 2015 - 2026 (USD Million)
Figure Granulocyte-Colony Stimulating Factor (G-CSF) Bio-pharma market, 2015 - 2026 (USD Million)
Figure Interferons Bio-pharma market, 2015 - 2026 (USD Million)
Figure Recombinant Human Insulin Bio-pharma market, 2015 - 2026 (USD Million)
Figure Erythropoietin Bio-pharma market, 2015 - 2026 (USD Million)
Figure Vaccines Bio-pharma market, 2015 - 2026 (USD Million)
Figure Growth Hormones Bio-pharma market, 2015 - 2026 (USD Million)
Figure Purified Proteins Bio-pharma market, 2015 - 2026 (USD Million)
Figure Others Bio-pharma market, 2015 - 2026 (USD Million)
Figure Metabolic Disorders market, 2015 - 2026 (USD Million)
Figure Oncology market, 2015 - 2026 (USD Million)
Figure Neurological Disorders market, 2015 - 2026 (USD Million)
Figure Cardiovascular Diseases market, 2015 - 2026 (USD Million)
Figure Inflammatory and Infectious Diseases market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Bio-pharma market, by country, 2015 - 2026 (USD Million)
-
Table North America Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table North America Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table North America Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Canada Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Canada Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Europe Bio-pharma market, by country, 2015 - 2026 (USD Million)
-
Table Europe Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Europe Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Europe Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Germany Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Germany Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table France Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table France Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Italy Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Italy Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Spain Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Spain Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Bio-pharma market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table China Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table China Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Japan Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Japan Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table India Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table India Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Bio-pharma market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table MEA Bio-pharma market, by country, 2015 - 2026 (USD Million)
-
Table MEA Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table MEA Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table MEA Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Bio-pharma market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Bio-pharma market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Bio-pharma market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Novartis AG GlaxoSmithKline Plc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Abbott Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck & Co., Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca PLC Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Company Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biogen Idec Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F Hoffmann-La Roche AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AbbVie Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eli Lilly and Company Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck & Co, Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F. Hoffmann-La Roche AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
